Advertisement
Advertisement
U.S. Markets close in 1 hr 49 mins
Advertisement
Advertisement
Advertisement
Advertisement

La Jolla Pharmaceutical Company (LJPC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2000-0.1000 (-3.03%)
As of 02:04PM EDT. Market open.
Advertisement

La Jolla Pharmaceutical Company

201 Jones Road
Suite 400
Waltham, MA 02451
United States
617 715 3600
https://www.lajollapharmaceutical.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees61

Key Executives

NameTitlePayExercisedYear Born
Mr. Larry G. EdwardsPres, CEO & Director749.17kN/A1972
Mr. Michael S. HearneCFO & Sec.186.04kN/A1963
Dr. Lakhmir S. Chawla M.D.Consultant478.97kN/A1971
Ms. Paula RusuVP of OperationsN/AN/AN/A
Ms. Sandra VedrickSr. Director of Investor Relations & HRN/AN/AN/A
Mr. Luke SeikkulaSr. VP of Pharmaceutical OperationsN/AN/A1964
Mr. Stewart M. KrollChief Devel. OfficerN/AN/A1959
Mr. Mark D. WilliamsSr. VP of Medical AffairsN/AN/AN/A
Mr. Tony N. Hodges FACP, M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Corporate Governance

La Jolla Pharmaceutical Company’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement